mecasermin: Clinical Trials

13 trials of mecasermin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 4 terminated. 13 Phase 2, 5 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 213Completed 9, Terminated 4
Phase 15Completed 4, Terminated 1
Phase 33Completed 2, Terminated 1

Follow mecasermin: new trials by email Literature Review of mecasermin trials Research Report on mecasermin

Trials (filtered) newest first · largest first

All 13 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
IGF-1 Treatment for Individuals With Short Stature Due to PAPP-A2 Deficiency
Increlex - Short Stature
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati72015-12-212024-02-28
A Pilot Treatment Study of Insulin-Like Growth Factor-1 (IGF-1) in Autism Spectrum Disorder
IGF-1, Placebo/saline - Autism Spectrum Disorder
Phase 2TerminatedIcahn School of Medicine at Mount Sinai32014-05-012024-02-08
Treatment of Rett Syndrome With Recombinant Human IGF-1
Recombinant Human Insulin Growth Factor 1 (rhIGF-1), Placebo - Rett Syndrome
Phase 2CompletedBoston Children's Hospital302013-01-012018-03-26
Clinical Trial in 22q13 Deletion Syndrome(Phelan-McDermid Syndrome)
Insulin-Like Growth Factor-1 (IGF-1), Normal saline - 22q13 Deletion Syndrome, Phelan-McDermid Syndrome
Phase 2CompletedIcahn School of Medicine at Mount Sinai192012-02-012022-05-12
Evaluation of the Safety and Efficacy of Using Insulin-like Growth Factor-1 in Patients With a Heart Attack
mecasermin, 0.9% sodium chloride injection - Heart Failure, Myocardial Infarction
Phase 1 / Phase 2CompletedUniversity College Cork472011-10-012017-03-30
Safety and Efficacy Study of IGF-1 in Duchenne Muscular Dystrophy
IGF-1 - Duchenne Muscular Dystrophy
Phase 1 / Phase 2CompletedChildren's Hospital Medical Center, Cincinnati442010-11-012021-01-20
Effect of Increlex® on Children With Crohn Disease
rhIGF (Increlex) - Crohn Disease
Phase 2 / Phase 3TerminatedNationwide Children's Hospital32008-10-012018-03-02
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
NutropinAq® (Somatropin [rDNA origin]), Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin]) - Insulin-like Growth Factor-1 Deficiency
Phase 2TerminatedIpsen1062007-12-012023-03-30
Treatment for Growth Failure in Patients With X-Linked Severe Combined Immunodeficiency: Phase 2 Study of Insulin-Like Growth Factor-1
Increlex - Growth Failure, X-linked Severe Combined Immunodeficiency (XSCID)
Phase 1 / Phase 2TerminatedNational Institute of Allergy and Infectious Diseases (NIAID)62007-06-012015-07-03
Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents
RhIGF-1 - Anorexia Nervosa
Phase 1 / Phase 2CompletedMassachusetts General Hospital162007-03-012021-11-18
Recombinant Human Insulin-Like Growth Factor (rhIGF-1) Treatment of Short Stature Associated With IGF-1 Deficiency
rhIGF-1 (mecasermin) for a period of 86 weeks - Insulin-Like Growth Factor-1 Deficiency, Growth Disorders
Phase 2 / Phase 3CompletedIpsen452005-07-012020-07-27
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerability and Effect/Efficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 (rhIGF) (CEP-151) in Multiple Sclerosis (MS) Patients
rhIGF-1 (CEP-151) - Multiple Sclerosis
Phase 2CompletedNational Institute of Neurological Disorders and Stroke (NINDS)151997-07-012008-03-04
Long-Term Treatment With rhIGF-1 in GHIS
mecasermin - Growth Hormone Insensitivity Syndrome
Phase 2 / Phase 3CompletedIpsen921991-05-202023-07-06

Conditions studied

Autism Spectrum Disorder (2)  ·  Anorexia Nervosa (1)  ·  Autistic Disorder (1)  ·  Crohn Disease (1)  ·  Dwarfism (1)  ·  Failure to Thrive (1)  ·  Growth Disorders (1)  ·  Heart Failure (1)  ·  Inflammatory Bowel Diseases (1)  ·  Insulin-Like Growth Factor I Deficiency (1)  ·  Laron Syndrome (1)  ·  Multiple Sclerosis (1)  ·  Muscular Dystrophy, Duchenne (1)  ·  Myocardial Infarction (1)  ·  Puberty, Delayed (1)

Sponsors

Ipsen (3)  ·  Children's Hospital Medical Center, Cincinnati (2)  ·  Icahn School of Medicine at Mount Sinai (2)  ·  Boston Children's Hospital (1)  ·  Massachusetts General Hospital (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  National Institute of Neurological Disorders and Stroke (NINDS) (1)  ·  Nationwide Children's Hospital (1)  ·  University College Cork (1)

Countries

United States (11)  ·  Ireland (1)  ·  Netherlands (1)

Top investigators

Alexander Kolevzon, MD (2)  ·  Dana S. Hardin, MD (1)  ·  Gajanathan Muthuvel, MD (1)  ·  Madhu Misra (1)  ·  Meilan Rutter, MD (1)  ·  Mustafa Sahin, MD, PhD (1)  ·  Noel Caplice, MB, PhD (1)  ·  Philippe Backeljauw, MD (1)  ·  Suk S De Ravin, M.D. (1)

Results publications

PMID 17192294, PMID 25685306, PMID 29029190, PMID 35395866, PMID 36646053, PMID 37811711, PMID 40351246

NIH funding

2019 (2), R34MH100276 (1)